Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist used primarily for the prevention of nausea and vomiting associated with cancer chemotherapy. The pharmaceutical active ingredient is generally supplied as Palonosetron Hydrochloride, a crystalline hydrochloride salt of the active (S)-configured compound. The current USP-NF monograph identifies Palonosetron Hydrochloride as (S)-2-[(3S)-quinuclidin-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride, with CAS Registry Number 135729-62-3 and molecular weight 332.87 g/mol.
The FDA describes Palonosetron Hydrochloride as a white to off-white crystalline powder, freely soluble in water, soluble in propylene glycol and slightly soluble in ethanol and 2-propanol. The drug substance is synthesized as a single isomer.
Palonosetron selectively blocks 5-hydroxytryptamine type 3 (5-HT3) receptors. Chemotherapy can stimulate serotonin release from enterochromaffin cells in the gastrointestinal tract, which activates 5-HT3 receptors and contributes to the vomiting reflex. By antagonizing these receptors, palonosetron suppresses the serotonergic signaling involved in chemotherapy-induced nausea and vomiting.
Compared with first-generation 5-HT3 antagonists, palonosetron has a relatively long elimination half-life, supporting its use for prevention of both acute and delayed chemotherapy-induced nausea and vomiting. FDA documentation identifies palonosetron as a 5-HT3 receptor antagonist used in oncology supportive care.
Palonosetron Hydrochloride is used in pharmaceutical formulations for the prevention of acute nausea and vomiting associated with moderately emetogenic chemotherapy and, depending on the specific formulation and regulatory indication, other chemotherapy-related nausea and vomiting settings.
It is also used in combination products. FDA documentation for the intravenous combination product AKYNZEO identifies palonosetron hydrochloride as the 5-HT3 receptor antagonist component.
Palonosetron Hydrochloride has a current USP-NF monograph. The USP definition specifies 98.0%–102.0%, calculated on the dried basis. Identification includes infrared spectroscopy, chromatographic retention-time comparison and chloride identification. The USP assay uses liquid chromatography with UV detection at 210 nm.
The current USP impurity procedure controls several named related substances, including Palonosetron Enantiomer, Related Compounds B, C, D and E, together with Related Compound A under a separate chromatographic procedure. The reporting threshold is 0.05%.
As a synthetic small-molecule API, Palonosetron Hydrochloride can be evaluated using validated chromatographic and physicochemical methods. Important quality attributes include assay, related substances, stereochemical purity, pH, loss on drying, residue on ignition and residual solvents.
Because palonosetron is stereochemically defined, enantiomeric purity is particularly important. The current USP monograph specifically controls the palonosetron enantiomer at NMT 0.1%, demonstrating that stereochemical control is an explicit pharmacopoeial quality attribute.
For commercial API manufacturing, the applicable current pharmacopoeial specification, approved regulatory dossier and validated analytical procedures should be used as the final quality standard.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.0 – 6.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |